Zobrazeno 1 - 10 of 32 pro vyhledávání: '"Melchior C. Nierman"'
1
Akademický článek
Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
Autor: Myrthe M. A. Toorop, Nienke vanRein, Melchior C. Nierman, Helga W. Vermaas, Menno V. Huisman, Felix J. M. van derMeer, Suzanne C. Cannegieter, Willem M. Lijfering
Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 586-593 (2020)
Abstract Background Many patients who used vitamin K antagonists (VKAs) for long‐term prevention of thromboembolism are now actively switched to a direct oral anticoagulant (DOAC). Strict adherence to a DOAC is crucial for its success. However, the
Externí odkaz: https://doaj.org/article/d66244669c374611bb64e83c57f133f9
Zobrazit plný text záznamu
2
Akademický článek
Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
Autor: Eleonora Camilleri, Nienke van Rein, Felix J. M. van der Meer, Melchior C. Nierman, Willem M. Lijfering, Suzanne C. Cannegieter, The Dutch COVID & Thrombosis Coalition
Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 7, Pp n/a-n/a (2021)
Abstract Background Coagulopathy has been reported in severely ill patients with coronavirus disease 2019 (COVID‐19). It is unclear whether outpatients with COVID‐19 who are treated with vitamin K antagonists (VKAs) have unstable anticoagulation.
Externí odkaz: https://doaj.org/article/3c754c07dfc24c7da8229b72505e669e
Zobrazit plný text záznamu
3
Akademický článek
Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial
Autor: Arno W Hoes, Frans H Rutten, Menno V Huisman, Geert-Jan Geersing, Linda P T Joosten, Sander van Doorn, Melchior C Nierman, Nynke M Wiersma, Huiberdina L Koek, Martin E W Hemels, Kit C Roes, Rutger M van den Bor, Wim F Buding
Publikováno v: BMJ Open, Vol 9, Iss 12 (2019)
Introduction Clinical guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF). Frail elderly were under-represented in the landma
Externí odkaz: https://doaj.org/article/6f52ec45918b42bb88865eb7646f4c18
Zobrazit plný text záznamu
4
Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients
Autor: Felix J. M. van der Meer, Melchior C Nierman, Laura M. Faber, Marieke J. H. A. Kruip, Myrthe M A Toorop, Suzanne C. Cannegieter, Qingui Chen, Lies Goede, Willem M. Lijfering
Publikováno v: Journal of Thrombosis and Haemostasis. WILEY
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 20(2), 339-352. WILEY
Journal of Thrombosis and Haemostasis, 20(2), 339-352. Wiley-Blackwell Publishing Ltd
Background: Non-valvular atrial fibrillation (NVAF) patients are advised to switch from a vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) when time in therapeutic range (TTR) is low. Objective: To examine if pre-switch TTR determines p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1be27352eceecdb8faf20390030e451
https://doi.org/10.1111/jth.15592
Zobrazit plný text záznamu
6
Self-reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
Autor: Menno V. Huisman, Helga W. Vermaas, Willem M. Lijfering, Felix J. M. van der Meer, Nienke van Rein, Suzanne C. Cannegieter, Melchior C Nierman, Myrthe M A Toorop
Publikováno v: Research and practice in thrombosis and haemostasis, 4(4), 586-593. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, 4(4), 586-593. WILEY
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 586-593 (2020)
Research and Practice in Thrombosis and Haemostasis
Background Many patients who used vitamin K antagonists (VKAs) for long‐term prevention of thromboembolism are now actively switched to a direct oral anticoagulant (DOAC). Strict adherence to a DOAC is crucial for its success. However, therapy adhe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b259f122da5dbc015316d5c7214c93a4
https://doi.org/10.1002/rth2.12316
Zobrazit plný text záznamu
7
Stability of vitamin K antagonist anticoagulation after COVID-19 diagnosis
Autor: Felix J. M. van der Meer, Eleonora Camilleri, Willem M. Lijfering, Suzanne C. Cannegieter, Nienke van Rein, Melchior C Nierman
Publikováno v: Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, 5(7). WILEY
Research and practice in thrombosis and haemostasis, 5(7):e12597. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 7, Pp n/a-n/a (2021)
Background Coagulopathy has been reported in severely ill patients with coronavirus disease 2019 (COVID‐19). It is unclear whether outpatients with COVID‐19 who are treated with vitamin K antagonists (VKAs) have unstable anticoagulation. Objectiv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfd02c002ef0b64086e821cd4bcbbb6c
https://hdl.handle.net/1887/3276465
Zobrazit plný text záznamu
9
Akademický článek
Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia
Autor: Frank G. Schaap, Melchior C. Nierman, Jimmy F.P. Berbée, Hiroaki Hattori, Philippa J. Talmud, Stefan F.C. Vaessen, Patrick C.N. Rensen, Robert A.F.M. Chamuleau, Jan Albert Kuivenhoven, Albert K. Groen
Publikováno v: Journal of Lipid Research, Vol 47, Iss 10, Pp 2333-2339 (2006)
The relevance of apolipoprotein A-V (apoA-V) for human lipid homeostasis is underscored by genetic association studies and the identification of truncation-causing mutations in the APOA5 gene as a cause of type V hyperlipidemia, compatible with an LP
Externí odkaz: https://doaj.org/article/71706867a91f493881928d7c88a9851d
Zobrazit plný text záznamu
10
Finding very high lipoprotein(a): the need for routine assessment
Autor: Paul Knaapen, Erik S.G. Stroes, Pauline C E Schuitema, Nick S. Nurmohamed, Shirin Ibrahim, Steven A J Chamuleau, Melchior C. Nierman, Johan Fischer, Yannick Kaiser
Publikováno v: Nurmohamed, N S, Kaiser, Y, Schuitema, P C E, Ibrahim, S, Nierman, M, Fischer, J C, Chamuleau, S A J, Knaapen, P & Stroes, E S G 2022, ' Finding very high lipoprotein(a) : the need for routine assessment ', European Journal of Preventive Cardiology, vol. 29, no. 5, pp. 769-776 . https://doi.org/10.1093/eurjpc/zwab167
European journal of preventive cardiology, 29(5), 769-776. SAGE Publications Ltd
European Journal of Preventive Cardiology, 29(5), 769-776. SAGE Publications Ltd
Aims To validate the reported increased atherosclerotic cardiovascular disease (ASCVD) risk associated with very high lipoprotein(a) [Lp(a)] and to investigate the impact of routine Lp(a) assessment on risk reclassification. Methods and results We pe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afbeb872d29ae92707c212cffcbf3a9
https://pubmed.ncbi.nlm.nih.gov/34718514
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje